The US drug regulator warned Wockhardt Ltd’s UK subsidiary CP Pharmaceuticals Ltd (currently known as Wockhardt UK Ltd) over violations of quality norms at its manufacturing plant in Wrexham.
Wockhardt acquired CP Pharma in 2003 for £10.85 million (Rs.82.46 crore then), key to expanding in Europe, a market which contributed 48% to total revenue in year ended March.
The FDA’s warning to the UK subsidiary found fault within three key areas—prevention of contamination, investigating the failure of production batches or components to meet specifications and assuring appropriate standards for product strength, quality and purity.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: